Improved Treatment of Distal Radius Fractures Using an Image-Guided, Percutaneous Delivery of a Novel Bone Adhesive
使用图像引导、经皮输送新型骨粘合剂改善桡骨远端骨折的治疗
基本信息
- 批准号:10380629
- 负责人:
- 金额:$ 62.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-04-01 至 2024-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdhesivesAnimal ModelAnimalsAnnual ReportsBariumBiocompatible MaterialsBone CementsBone remodelingCadaverCarpal Tunnel SyndromeCase StudyChemistryClinicalComplementComplexComplex Regional Pain SyndromesComplicationCompression FractureContrast MediaDevelopmentDevicesDistalElderlyEvaluationFailureFluoroscopyFormulationFractureFundingGovernmentHandHigh PrevalenceHistologyHospitalsHumanInfectionInferiorInjectionsInjuryInvestigationLeadMechanicsMedicalMedicareMetalsMetatarsal bone structureMissionModelingMonitorOpen FracturesOperating RoomsOperative Surgical ProceduresOrthopedicsOsteoporosisOsteoporoticOutcome StudyPatientsPerformancePersonsPhaseProceduresPropertyPublishingQuality of lifeRadialRadius FracturesReportingResearchRuptureSampling StudiesSheepSurgeonTechnologyTendon structureTestingTimeTranslationsTraumaUpper Extremityagedaging populationbasebiomechanical testbonebone healingcone-beam computed tomographyfallshealingimage guidedimprovedin vivoinnovationirritationmechanical propertiesmortalitynovelolder patientpaymentphase 2 studyprimary outcomeprocedure costresearch and developmentsample fixationscaffoldstandard of carestanding heightusability
项目摘要
Project Abstract/Summary
Falls from standing height and other low-energy trauma account for 87% of all orthopedic fractures among the
elderly. Distal radius fractures (DRF) are one of the most common types of these fractures, with approximately
40% of the more than 675,000 DRF cases reported annually in the U.S. occurring in people aged 65 years or
older. Unfortunately, these injuries result in difficulty performing the most basic daily tasks and, for elderly
patients, can lead to a loss of independence, a reduction in quality of life, and even increased mortality.
The current standard of care for DRF injuries is open reduction internal fixation (ORIF) procedures that involve
placement of metal hardware such as volar plates and/or K-wires. Results of these open surgical approaches
have been mixed; complication rates have been reported to be as high as 36% in the elderly and involve the
onset of carpal tunnel syndrome, complex regional pain syndrome, and have led to tendon irritation and rupture,
deep infections, and the need to re-operate to remove the plates.
To address this issue LaunchPad Medical (LPM) has developed Tetranite® (TN), a novel bone adhesive
biomaterial that can bond bone fragments together, fill bone voids, and adhere bone to metal. Over time this
innovative material acts as a scaffold, promoting healing and allowing bone to grow through it to ultimately
replace it with new, vital bone. TN’s robust bond strength, when subjected to shear loading to the various
substrates, has been shown to be significantly greater than non-adhesive bone cements on the market. Yet
when properly mixed, TN’s flow properties make it ideal for percutaneous delivery. Uniquely, TN can be loaded
with BaSO4 without significant degradation to its mechanical properties, making it possible for a surgeon to
monitor its placement in vivo via fluoroscopy in real time and without the need for open surgery.
In Phase I of this project the TN adhesive chemistry was characterized and optimized to yield a product with
sufficient mechanical and microstructural properties to fixate upper extremity bone fractures on a stand-alone
basis (without the use of metal fixation hardware). Preliminary cadaver studies have demonstrated the effective
percutaneous treatment using the optimized formulation. Building on this successful Phase I project, and other
preliminary R & D, TN’s translation to a clinical indication for treating DRF injuries will continue in the proposed
Phase II study through the completion of the following: Aim 1: Optimization of the Percutaneous Delivery of
TN for DRF Procedures and Aim 2: Demonstration of the Safe and Effective Use of TN in a Large Animal
Study.
The results from this translational animal study, complemented with surgeon validated simulated use cadaver
testing, will be used to as the basis for filing an Investigational Device Exemption (IDE) with the FDA to initiate
human studies. Long term, LPM’s mission is to provide surgeons with a novel product that will enhance fixation,
reduce complications and revision surgeries associated with DRF procedures in the elderly.
项目摘要/摘要
从站立高度的福尔斯跌倒和其他低能量创伤占所有骨科骨折的87%,
老人桡骨远端骨折(DRF)是这些骨折中最常见的类型之一,大约
在美国每年报告的超过675,000例DRF病例中,有40%发生在65岁或以上的人群中。
老了不幸的是,这些损伤导致难以执行最基本的日常任务,
患者,可能导致丧失独立性,生活质量下降,甚至死亡率增加。
目前DRF损伤的护理标准是切开复位内固定(ORIF)手术,包括
放置金属硬件,如掌侧接骨板和/或克氏针。这些开放手术方法的结果
混合;据报道,老年人的并发症发生率高达36%,
腕管综合征的发病,复杂的区域疼痛综合征,并导致肌腱刺激和断裂,
深部感染,需要再次手术取出钢板。
为了解决这一问题,LaunchPad Medical(LPM)开发了一种新型骨粘合剂Tetranite®(TN)
生物材料可以将骨碎片粘合在一起,填充骨空隙,并将骨粘附到金属上。随着时间的推移,
创新的材料作为支架,促进愈合,并允许骨骼通过它生长,
用新的有活力的骨头代替TN的强大的粘结强度,当受到剪切负荷,以各种
已经显示出显著大于市场上的非粘性骨水泥。然而
当适当混合时,TN的流动特性使其成为经皮输送的理想选择。独特的是,TN可以装载
与BaSO 4一起使用,而不会显著降低其机械性能,使外科医生能够
通过荧光透视在真实的时间内监测其在体内的放置,而不需要开放手术。
在该项目的第一阶段,对TN粘合剂化学进行了表征和优化,以产生具有以下特性的产品:
具有足够的机械和微观结构特性,可将上肢骨折固定在独立的
基础(不使用金属固定硬件)。初步的尸体研究表明,
使用优化的制剂进行经皮治疗。在这一成功的第一阶段项目的基础上,
初步研发,TN的翻译为治疗DRF损伤的临床适应症将继续在拟议的
II期研究,通过完成以下内容:目标1:优化经皮给药
TN用于DRF程序和目的2:证明TN在大型动物中的安全有效使用
Study.
该转化动物研究的结果,以及外科医生确认的模拟使用尸体
试验,将用作向FDA提交试验用器械豁免(IDE)的基础,
人类研究从长远来看,LPM的使命是为外科医生提供一种新型产品,
减少与老年人DRF手术相关的并发症和翻修手术。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Brian Hess其他文献
Brian Hess的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Brian Hess', 18)}}的其他基金
Commercialization of an Improved Treatment of Extremity Fractures Using a Regenerative Bone Adhesive to Accelerate Bone Healing in Aging Patients
使用再生骨粘合剂加速老年患者骨愈合的四肢骨折改进治疗方法的商业化
- 批准号:
10822079 - 财政年份:2023
- 资助金额:
$ 62.45万 - 项目类别:
Improved Treatment of Vertebral Compression Fractures for Elderly Patients Using an Image-Guided, Percutaneous Delivery of a Novel Bone Adhesive
使用图像引导、经皮输送新型骨粘合剂改善老年患者椎体压缩性骨折的治疗
- 批准号:
10547209 - 财政年份:2022
- 资助金额:
$ 62.45万 - 项目类别:
A Novel Bioresorbable Bone Adhesive Used to Fixate Cranial Flaps and Reduce Infection Rates
一种新型生物可吸收骨粘合剂,用于固定颅骨瓣并降低感染率
- 批准号:
10010631 - 财政年份:2020
- 资助金额:
$ 62.45万 - 项目类别:
相似海外基金
I-Corps: Translation Potential of Peptidic Ensembles as Novel Bio-adhesives
I-Corps:肽整体作为新型生物粘合剂的转化潜力
- 批准号:
2409620 - 财政年份:2024
- 资助金额:
$ 62.45万 - 项目类别:
Standard Grant
Architectural design of active adhesives
活性粘合剂的结构设计
- 批准号:
2403716 - 财政年份:2024
- 资助金额:
$ 62.45万 - 项目类别:
Standard Grant
Design of non-swellable adhesives for brain surgery using cyclodextrin inclusion polymer
使用环糊精包合物聚合物脑外科不可溶胀粘合剂的设计
- 批准号:
23H01718 - 财政年份:2023
- 资助金额:
$ 62.45万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Meta-material adhesives for improved performance and functionalisation of bondlines
超材料粘合剂可提高粘合层的性能和功能化
- 批准号:
EP/W019450/1 - 财政年份:2023
- 资助金额:
$ 62.45万 - 项目类别:
Fellowship
Light-propelled dental adhesives with enhanced bonding capability
具有增强粘合能力的光驱动牙科粘合剂
- 批准号:
10741660 - 财政年份:2023
- 资助金额:
$ 62.45万 - 项目类别:
DMREF: Accelerating the Design of Adhesives with Nanoscale Control of Thermomechanical Properties
DMREF:通过热机械性能的纳米级控制加速粘合剂的设计
- 批准号:
2323317 - 财政年份:2023
- 资助金额:
$ 62.45万 - 项目类别:
Continuing Grant
Mag-Cure: A novel method for magnetically induced bonding and de-bonding of thermoset adhesives in the Automotive Industry
Mag-Cure:汽车行业中热固性粘合剂磁感应粘合和脱粘的新方法
- 批准号:
10062336 - 财政年份:2023
- 资助金额:
$ 62.45万 - 项目类别:
Collaborative R&D
Biodegradable, Biocompatible Pressure Sensitive Adhesives
可生物降解、生物相容性压敏粘合剂
- 批准号:
10677869 - 财政年份:2022
- 资助金额:
$ 62.45万 - 项目类别:
Poly(glycerol carbonate) pressure sensitive adhesives for the in vivo closure of alveolar pleural fistulae
用于体内闭合肺泡胸膜瘘的聚(甘油碳酸酯)压敏粘合剂
- 批准号:
10746743 - 财政年份:2022
- 资助金额:
$ 62.45万 - 项目类别:
Enhanced bio-production of difficult to make peptide ingredients for specialty adhesives and personal care
增强用于特种粘合剂和个人护理品的难以制造的肽成分的生物生产
- 批准号:
10021363 - 财政年份:2022
- 资助金额:
$ 62.45万 - 项目类别:
Investment Accelerator